Welcome to our dedicated page for Aimfinity Investment I SEC filings (Ticker: AIMWF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Aimfinity Investment I's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Aimfinity Investment I's regulatory disclosures and financial reporting.
Aimfinity Investment Corp. I entered into a small financing arrangement to extend the deadline for completing its initial business combination. On February 28, 2026, the company issued an unsecured promissory note for $500 to I-Fa Chang, designated by the sponsor, and deposited the same amount into its trust account as a monthly extension payment.
This fifth of up to nine allowed extensions moves the business combination deadline from February 28, 2026 to March 28, 2026. Under an existing exchange agreement, the note balance will automatically convert into PubCo ordinary shares at $10.00 per share upon closing the proposed business combination with Docter Inc., unless repaid earlier. The note was issued under a private placement exemption, and the company also released a press statement announcing the extension.
Aimfinity Investment Corp. I received an amended Schedule 13G/A showing that a group of Harraden Circle investment entities and Frederick V. Fortmiller, Jr. now report beneficial ownership of 0 shares, or 0%, of the Class A common stock as of 12/31/2025.
The filing states this is an exit filing, confirming that these reporting persons have ceased to be beneficial owners of more than five percent of Aimfinity’s Class A shares and no longer hold voting or dispositive power over the stock.
Aimfinity Investment Corp. I disclosed that it issued an unsecured promissory note for $500 to I-Fa Chang, the sponsor’s designee, to fund a monthly extension payment into the trust account for public shareholders. This payment extends the deadline to complete its initial business combination by one month, from January 28, 2026 to February 28, 2026.
The new extension is the fourth of up to nine one‑month extensions authorized under a prior charter amendment, each requiring a $500 deposit into the trust account. Upon closing of the proposed business combination with Docter Inc., any unpaid balance of the note will automatically convert into PubCo ordinary shares at a conversion price of $10.00 per share. The note was issued under a Section 4(a)(2) exemption, and the company also furnished a press release announcing the extension.
Aimfinity Investment Corp. I disclosed that it issued a $500 unsecured promissory note to I-Fa Chang, a manager of its sponsor’s LLC, to fund a monthly extension payment into the SPAC trust account. This payment allows Aimfinity to extend the deadline to complete its initial business combination by one month, from December 28, 2025 to January 28, 2026, representing the third of up to nine one‑month extensions authorized under a prior charter amendment.
Under an existing exchange agreement, the note’s outstanding balance will automatically convert into PubCo ordinary shares at $10.00 per share if the business combination between Aimfinity and Docter Inc. closes, unless repaid earlier. The note was issued under a private offering exemption from registration, and the company also furnished a press release announcing the new extension while reiterating extensive forward‑looking statement and transaction risk disclosures.
Aimfinity Investment Corp. I, a SPAC, reported net income of $117,673 for the nine months ended September 30, 2025, driven by $630,505 of interest on cash and investments in its trust account, which more than offset $512,832 of formation and operating costs. The trust account balance fell to $14,294,569 from $36,940,228 at year-end 2024, mainly after redeeming 1,996,522 Class A shares for a total of $23,778,577.
Outside the trust, cash was only $3,517 with a working capital deficit of $2,785,815, and management concluded that these conditions, together with the limited time left to complete a merger, raise substantial doubt about the company’s ability to continue as a going concern. The SPAC continues to pursue a business combination with Docter Inc., has amended its charter multiple times to extend its deadline (with deposits totaling $1,808,413 into the trust for extensions), and has converted $1,500,000 of sponsor loans into 150,000 private units while restructuring deferred underwriting fees into a mix of cash and stock payable at closing.
Aimfinity Investment Corp. I disclosed that shareholders approved changes to its charter that let the company extend the deadline to complete its initial business combination in one-month increments, up to nine months, to July 28, 2026, by depositing $500 into its trust account for each extension. The charter was also amended to remove the requirement that any business combination leave the company with at least $5,000,001 of net tangible assets.
On November 28, 2025, Aimfinity issued an unsecured promissory note for $500 to I-Fa Chang, designated by the sponsor, to fund the first new monthly extension, moving the transaction deadline from November 28, 2025 to December 28, 2025. Upon closing of its proposed business combination with Docter Inc., any unpaid balance of this note will automatically convert into PubCo ordinary shares at a price of $10.00 per share.
Aimfinity Investment Corp. I reported shareholder approval of an amendment allowing extensions of its business combination deadline to October 28, 2025, with up to nine one‑month extensions to July 28, 2026 by depositing $500 per month. The company elected to extend to November 28, 2025 and deposited $500 into its trust account.
The company was informed that 572,989 Class A ordinary shares were tendered for redemption in connection with the extension process. In addition, 503,472 Class A ordinary shares remain subject to redemption upon the closing of the proposed business combination with Docter Inc., based on prior requests. The business combination had previously been approved at the March 27, 2025 meeting.
Aimfinity’s securities trade over-the-counter: units (AIMUF), new units (AIMTF), and Class 1 redeemable warrants (AIMWF), each warrant exercisable for one Class A ordinary share at an exercise price of $11.50.
Aimfinity Investment Corp. I reported shareholder approval of two charter amendments to keep its SPAC process moving. The extension amendment lets the company extend its business combination deadline by up to nine one‑month periods to July 28, 2026, with a deposit of $500 into the trust account for each extension. The NTA amendment removes the prior requirement to maintain net tangible assets of at least $5,000,001 in connection with redemptions or closing.
To fund the first extension from October 28, 2025 to November 28, 2025, the company issued a $500 unsecured promissory note to the sponsor’s designee, exchangeable at closing of the Docter Inc. business combination into PubCo ordinary shares at $10.00 per share. The extension proposal passed with 2,785,849 votes for, 2,097 against, 4 abstain; the NTA change passed with 2,787,946 for, 0 against, 4 abstain. As of September 29, 2025, shares outstanding were 1,758,476 Class A and 2,012,500 Class B.
Aimfinity Investment Corp. I filed an 8-K to supplement its proxy materials for the Extraordinary Meeting. The company extended the deadline for public shareholders to submit redemption requests or reversals from October 23, 2025, 5:00 p.m. ET to October 27, 2025, 11:00 a.m. ET.
The filing clarifies that holders who previously elected to redeem in connection with the Docter Business Combination must reverse or withdraw that prior request and then submit a new redemption election for this Extraordinary Meeting if they wish to redeem now. It also notes there is no assurance the meeting will be held if the Docter Business Combination is completed beforehand; any proposed closing date will be announced at least 2 business days in advance.
Meeting logistics are unchanged: the session remains on October 27, 2025 at the Taiwan location with virtual access. The record date remains September 29, 2025.